This site is intended for healthcare professionals
Abstract digital waveforms in blue and purple
FDA Drug information

Naproxen

Read time: 1 mins
Marketing start date: 23 Dec 2024
...
 

Summary of product characteristics


Effective Time

20230927

Version

5

Spl Product Data Elements

Naproxen Naproxen NAPROXEN NAPROXEN CROSCARMELLOSE SODIUM FERRIC OXIDE YELLOW MAGNESIUM STEARATE POVIDONE ZE10 Naproxen Naproxen NAPROXEN NAPROXEN CROSCARMELLOSE SODIUM FERRIC OXIDE YELLOW MAGNESIUM STEARATE POVIDONE yellow ZE9 Naproxen Naproxen NAPROXEN NAPROXEN CROSCARMELLOSE SODIUM FERRIC OXIDE YELLOW MAGNESIUM STEARATE POVIDONE ZE8

Application Number

ANDA078620

Brand Name

Naproxen

Generic Name

Naproxen

Product Ndc

65841-676

Product Type

HUMAN PRESCRIPTION DRUG

Route

ORAL

Package Label Principal Display Panel

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL NDC 65841-676-01 Naproxen tablets, 250 mg 100 Tablets Rx only NDC 65841-677-01 Naproxen tablets, 375 mg 100 Tablets Rx only NDC 65841-678-01 Naproxen tablets, 500 mg 100 Tablets Rx only Naproxen tablets Naproxen tablets Naproxen tablets

Spl Medguide

Manufactured by: Cadila Healthcare Ltd. India

Drug section

CME banner

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Disclaimer

The drug Prescribing Information (PI), including indications, contra-indications, interactions, etc, has been developed using the U.S. Food & Drug Administration (FDA) as a source (www.fda.gov).

Medthority offers the whole library of PI documents from the FDA. Medthority will not be held liable for explicit or implicit errors, or missing data.

Drugs appearing in this section are approved by the FDA. For regions outside of the United States, this content is for informational purposes only and may not be aligned with local regulatory approvals or guidance.